Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
AffiliationSt Vincent's University Hospital, Neurology, Dublin, Republic of Ireland., firstname.lastname@example.org
Drug Administration Schedule
Immunosuppressive Agents/*administration & dosage/economics
Multiple Sclerosis, Chronic Progressive/diagnosis/*drug
*Physician's Practice Patterns/economics
Practice Guidelines as Topic
Rural Health Services
Severity of Illness Index
Urban Health Services
MetadataShow full item record
CitationMult Scler. 2009 Dec;15(12):1528-31. Epub 2009 Dec 7.
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
AbstractDisease-modifying therapy is ineffective in disabled patients (Expanded Disability Status Scale [EDSS] > 6.5) with secondary progressive multiple sclerosis (MS) without relapses, or in primary progressive MS. Many patients with secondary progressive MS who initially had relapsing MS continue to use disease-modifying therapies. The enormous associated costs are a burden to health services. Regular assessment is recommended to guide discontinuation of disease-modifying therapies when no longer beneficial, but this is unavailable to many patients, particularly in rural areas. The objectives of this study are as follows: 1. To observe use of disease-modifying therapies in patients with progressive multiple sclerosis and EDSS > 6.5. 2. To examine approaches used by a group of international MS experts to stopping-disease modifying therapies in patients with secondary progressive MS without relapses. During an epidemiological study in three regions of Ireland (southeast Dublin city, and Wexford and Donegal Counties), we recorded details of disease-modifying therapies in patients with progressive MS and EDSS > 6.5. An e-questionnaire was sent to 26 neurologists with expert knowledge of MS, asking them to share their approach to stopping disease-modifying therapies in patients with secondary progressive MS. Three hundred and thirty-six patients were studied: 88 from southeast Dublin, 99 from Wexford and 149 from Donegal. Forty-four had EDSS > 6.5: 12 were still using disease-modifying therapies. Of the surveyed neurologists, 15 made efforts to stop disease-modifying therapies in progressive multiple sclerosis, but most did not insist. A significant proportion (12 of 44 patients with progressive MS and EDSS > 6.5) was considered to be receiving therapy without benefit. Eleven of the 12 were from rural counties, reflecting poorer access to neurology services. The costs of disease-modifying therapies in this group (>170,000 euro yearly) could be re-directed towards development of neurology services to optimize their management.
- How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
- Authors: Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS
- Issue date: 2007 Oct 9
- Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
- Authors: Minden S, Hoaglin D, Jureidini S, Hadden L, Frankel D, Komatsuzaki Y, Outley J
- Issue date: 2008 Jun
- Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
- Authors: Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Sénéchal O, Vermersch P
- Issue date: 2004 Mar 15
- Costs and quality of life of multiple sclerosis in Austria.
- Authors: Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, Kolleger H, Vass K
- Issue date: 2006 Sep
- The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
- Authors: Motamed MR, Najimi N, Fereshtehnejad SM
- Issue date: 2007 May